Guggenheim Upgrades Bristol Myers to Buy with $62 Target
Guggenheim raises Bristol Myers to Buy, citing low expectations, strong pipeline, and potential entry point for value-focused investors.
/ 13 items
#BMY↓
MapLight Therapeutics Gains from Bristol Myers’ ADEPT-2 Study Update
MapLight Therapeutics sees upside as Bristol Myers continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026.
Bayer's Stroke Prevention Drug Shows Promise, Reviving Hope for New Blood Clot Treatment Class
Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.
Repare Therapeutics to Be Acquired by XenoTherapeutics
Repare Therapeutics (RPTX) announces acquisition by XenoTherapeutics for $1.82/share plus contingent value rights, expected to close Q1 2026.
Bristol Myers & J&J Halt Key Heart Drug Trial After Weak Results
Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
Bristol Myers Squibb Defies Patent Cliff: Blockbuster Sales of Opdivo and Eliquis Drive Raised Forecast
BMS crushed Q3 goals and boosted its yearly forecast. New blockbusters like Opdivo and Eliquis cover losses from older generic drugs.